Early nod planned for clinical trials of all drugs and vaccines in India

12 June 2020

In a move expected to shave approval time for clinical trials to three months from the current 12 months, the Indian government has designated the Central Drugs Standard Control Organization (CDSCO) as the first point of registration for clinical trials of all drugs and vaccines.

Taking advantage of the opportunity provided by the COVID-19 pandemic to boost the healthcare system, the government has pushed through critical reforms to cut down the regulatory maze for faster clinical trials and boost R&D as well as propel innovation in vaccines and therapeutics.

Over 50 COVID-19 candidates are currently under clinical trials in India across 100 medical institutions and hospitals in the country.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK